title: Developing a Noninvasive Procedure Using Labeled Monoclonal Antibody Anti-VEGF (Bevacizumab) for Detection of Endometriosis.
abstract: The off-label use of bevacizumab labeled with 99mTc as a new radiopharmaceutical for imaging of endometriosis is a promising noninvasive, new clinical procedure. The bevacizumab in monoclonal antibodies targeted at vascular endothelial growth factor (VEGF) is superexpressed in cases of endometriosis. In this study we evaluate the imaging of endometriosis lesion in rats (induced to endometriosis) using bevacizumab-99mTc. The results showed that bevacizumab-99mTc imaged the lesion and support his use for Nuclear Medicine applied to gynecology. Also the results appointed that this radiopharmaceutical has a hepatobiliary excretion. It is important to notice that the dose used was almost 0,01% of the usual dose for the bevacizumab.
authors.affiliation: Laboratório de Pesquisa de Ciências Farmacêuticas, Unidade de Farmácia, Centro Universitário Estadual da Zona Oeste, Rio de Janeiro, RJ, Brazil.
authors.forename: Daniel Escorsim
authors.initials: DE
authors.lastname: Machado
authors.affiliation: Laboratório de Pesquisa de Ciências Farmacêuticas, Unidade de Farmácia, Centro Universitário Estadual da Zona Oeste, Rio de Janeiro, RJ, Brazil ; Programa de Pós-Graduação em Saúde Pública e Meio Ambiente, Escola Nacional de Saúde Pública, Fundação Oswaldo Cruz, Rio de Janeiro, RJ, Brazil.
authors.forename: Jamila Alessandra
authors.initials: JA
authors.lastname: Perini
authors.affiliation: University Hospital Pedro Ernesto, Nuclear Medicine Service, Rio de Janeiro, RJ, Brazil.
authors.forename: Margarida Maria Camoes
authors.initials: MM
authors.lastname: Orlando
authors.affiliation: Laboratory of Nanoradiopharmaceuticals, 21741706 Rio de Janeiro, RJ, Brazil.
authors.forename: Ralph
authors.initials: R
authors.lastname: Santos-Oliveira
mesh_terms: D020533:Angiogenesis Inhibitors / Q000737:chemistry / Q000493:pharmacokinetics; D000818:Animals; D000068258:Bevacizumab / Q000493:pharmacokinetics*; D004715:Endometriosis / Q000000981:diagnostic imaging* / Q000378:metabolism*; D005260:Female; D007553:Isotope Labeling / Q000379:methods; D008657:Metabolic Clearance Rate; D009928:Organ Specificity; D011877:Radionuclide Imaging / Q000379:methods*; D019275:Radiopharmaceuticals / Q000138:chemical synthesis / Q000493:pharmacokinetics; D051381:Rats; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D013667:Technetium; D014018:Tissue Distribution
chemical_list: D020533:Angiogenesis Inhibitors; D019275:Radiopharmaceuticals; D000068258:Bevacizumab; D013667:Technetium